[1] [1] Lim H, Devesa SS, Sosa JA, et al. Trends in thyroid cancer incidence and mortality in the United States, 1974—2013[J]. JAMA, 2017, 317(13): 1338-1348.

[2] [2] Morris LG, Sikora AG, Tosteson TD, et al. The increasing incidence of thyroid cancer: the influence of access to care[J]. Thyroid, 2013, 23(7): 885-891.

[3] [3] Zhai M, Zhang D, Long J, et al. The global burden of thyroid cancer and its attributable risk factor in 195 countries and territories: A systematic analysis for the Global Burden of Disease Study[J]. Cancer Med, 2021, 10(13): 4542-4554.

[4] [4] Schlumberger M, Sherman SI. Approach to the patient with advanced differentiated thyroid cancer[J]. Eur J Endocrinol, 2012, 166(1): 5-11.

[5] [5] Haigh PI, Urbach DR, Rotstein LE. AMES prognostic index and extent of thyroidectomy for well-differentiated thyroid cancer in the United States[J]. Surgery, 2004, 136(3): 609-616.

[6] [6] Schmitt E, Klein M, Bopp T. Th9 cells, new players in adaptive immunity[J]. Trends Immunol, 2014, 35(2): 61-68.

[7] [7] Koh B, Abdul Qayum A, Srivastava R, et al. A conserved enhancer regulates IL-9 expression in multiple lineages[J]. Nat Commun, 2018, 9(1): 4803.

[8] [8] Xiao X, Fan Y, Li J, et al. Guidance of super-enhancers in regulation of IL-9 induction and airway inflammation[J]. J Exp Med, 2018, 215(2): 559-574.

[9] [9] Verma M, Liu S, Michale L, et al. Experimental asthma persists in IL-33 receptor knockout mice because of the emergence of thymic stromal lymphopoietin-driven IL-9+and IL-13+type 2 innate lymphoid cell subpopulations[J]. J Allergy Clin Immunol, 2018, 142(3): 793-803. e8.

[10] [10] Wang Y, Shi J, Yan J, etal. Germinal-center development of memory B cells driven by IL-9 from follicular helper T cells[J]. Nat Immunol, 2017, 18(8): 921-930.

[11] [11] You FP, Zhang J, Cui T, et al. Th9 cells promote antitumor immunity via IL-9 and IL-21 and demonstrate atypical cytokine expression in breast cancer[J]. Int Immunopharmacol, 2017, 52: 163-167.

[12] [12] Rivera Vargas T, Humblin E, Vegran F, et al. TH9 cells in anti-tumor immunity[J]. Semin Immunopathol, 2017, 39(1): 39-46.

[13] [13] Ye ZJ, Zhou Q, Yin W, et al. Differentiation and immune regulation of IL-9-producing CD4+T cells in malignant pleural effusion[J]. Am J Respir Crit Care Med, 2012, 186(11): 1168-1179.

[14] [14] Benevides L, Costa RS, Tavares LA, etal. B lymphocyte-induced maturation protein 1 controls TH9 celldevelopment, IL-9production, and allergic inflammation[J]. J Allergy Clin Immunol, 2019, 143(3): 1119-1130. e3.

[15] [15] Lv X, Feng L, Ge X, et al. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma[J]. J Exp Clin Cancer Res, 2016, 35(1): 106.

[16] [16] Liu Y, Xie Y, Han X, et al. Th9/IL-9 may participate in the pathogenesis of multiple myeloma[J]. Int J Lab Hematol, 2024, 46(2): 322-328.

[17] [17] Chen T, Xue Y, Wang S, et al. Enhancement of T cell infiltration via tumor-targeted Th9 cell delivery improves the efficacy of antitumor immunotherapy of solid tumors[J]. Bioact Mater, 2023, 23: 508-523.

[18] [18] Gomez-Rodriguez J, Meylan F, Handon R, et al. Itk is required for Th9 differentiation via TCR-mediated induction of IL-2 and IRF4[J]. Nat Commun, 2016, 7: 10857.

[19] [19] Hu B, Li G, Ye Z, et al. Transcription factor networks in aged nave CD4 T cells bias lineage differentiation[J]. Aging Cell, 2019, 18(4): e12957.

[20] [20] Chauhan SR, Singhal PG, Sharma U, et al. Th9 cytokines curb cervical cancer progression and immune evasion[J]. Hum Immunol, 2019, 80(12): 1020-1025.

[21] [21] Angkasekwinai P, Chang SH, Thapa M, etal. Regulation of IL-9 expression by IL-25 signaling[J]. Nat Immunol, 2010, 11(3): 250-256.

[22] [22] Chen J, Zhao Y, Jiang Y, et al. Interleukin-33 contributes to the induction of Th9 cells and antitumor efficacy by dectin-1-activated dendritic cells[J]. Front Immunol, 2018, 9: 1787.

[23] [23] Xue G, Jin G, Fang J, et al. IL-4 together with IL-1 induces antitumor Th9 cell differentiation in the absence of TGF- signaling[J]. Nat Commun, 2019, 10(1): 1376.

[24] [24] Chakraborty S, Kubatzky KF, Mitra DK. An update on interleukin-9: from its cellular source and signal transduction to its role in immunopathogenesis[J]. Int J Mol Sci, 2019, 20(9): 2113.

[25] [25] Wang J, Sun M, Zhao H, et al. IL-9 exerts antitumor effects in colon cancer and transforms the tumor microenvironmentin vivo[J]. Technol Cancer Res Treat, 2019, 18: 1533033819857737.

[26] [26] Cai L, Zhang Y, Zhang Y, et al. Effect of Th9/IL-9 on the growth of gastric cancer in nude mice[J]. Onco Targets Ther, 2019, 12: 2225-2234.

[27] [27] Kim DH, Van Dyken SJ. ILC2s in high definition: decoding the logic of tissue-based immunity[J]. Trends Immunol, 2020, 41(1): 7-16.

[28] [28] Wan J, Cai W, Wang H, et al. Role of type 2 innate lymphoid cell and its related cytokines in tumor immunity[J]. J Cell Physiol, 2020, 235(4): 3249-3257.

[29] [29] Wan J, Wu Y, Huang L, et al. ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8+T cells[J]. Cancer Lett, 2021, 502: 34-43.

[30] [30] Chen T, Guo J, Cai Z, et al. Th9 cell differentiation and its dual effects in tumor development[J]. Front Immunol, 2020, 11: 1026.